Prophase Labs (PRPH) Q3 2024 earnings summary

Executive summary

• Aggressive capital raise executed to support launches of DNA Complete and DNA Expand, and to ramp up Pharmaloz Manufacturing (PMI) for the holiday season.

• Net revenue for Q3 2024 was $3.1 million, down from $8.4 million in Q3 2023, driven by declines in diagnostic services and consumer products due to reduced COVID-19 testing volumes and lower consumer product sales.

• Net loss for Q3 2024 was $6.6 million ($0.35 per share), compared to a net loss of $5.1 million ($0.30 per share) in Q3 2023, reflecting lower revenues and higher interest expenses.

• Strategic focus on reducing overhead and expenses by at least $6 million, including satisfaction of over $5 million in payables, with implementation expected before year-end.

• Multiple late-stage assets positioned for commercialization, including BE-Smart esophageal cancer test, Equivir antiviral, and DNA-based consumer products.

Financial highlights

• PMI expected to generate $15 million in revenue and $5 million+ in earnings over the next 12 months from the first manufacturing line.

• Second manufacturing line for PMI anticipated to add $20–$25 million in annual revenue, with a five-year contract under negotiation.

• Gross margin for Q3 2024 was negative 5.2%, compared to 27.8% in Q3 2023; for the nine months, gross margin was negative 11.6% versus 47.2% in the prior year.

• Adjusted EBITDA for Q3 2024 was negative $4.4 million, compared to negative $2.5 million in Q3 2023.

• Cash and cash equivalents as of September 30, 2024, were $1.1 million, with working capital at $13.5 million.

Outlook and guidance

• Expectation of at least $5 million in earnings from Pharmaloz next year, with overall financials projected to improve significantly.

• Significant sequential improvement in revenues and EBITDA expected in Q4 2024 and beyond, driven by subsidiary growth and strategic initiatives.

• Company plans to reduce overhead and expenses by approximately $6 million annually in 2025 to focus on core assets.

• Anticipated commercialization of BE-Smart esophageal cancer test within a year if LDT route is taken, or by early 2026 if FDA approval is required.

• Plans to break out DNA Complete and DNA Expand sales in Q4 results, with initial traction expected during the holiday season.